Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders
about
HIV-associated neurocognitive disorder--pathogenesis and prospects for treatmentInhibition of microglia activation as a phenotypic assay in early drug discoveryCurrent approaches to enhance glutamate transporter function and expressionInteractive Effects of Ethanol and HIV-1 Proteins on Novelty-Seeking Behaviors and Addiction-Related Gene ExpressionNicotine attenuates the effect of HIV-1 proteins on the neural circuits of working and contextual memoriesExposure to HIV-1 Tat in brain impairs sensorimotor gating and activates microglia in limbic and extralimbic brain regions of male mice.IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy.Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder.Glutamate metabolism and HIV-associated neurocognitive disorders.Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease.Chemokine co-receptor CCR5/CXCR4-dependent modulation of Kv2.1 channel confers acute neuroprotection to HIV-1 glycoprotein gp120 exposure.Small molecule glutaminase inhibitors block glutamate release from stimulated microglia.Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucinePilot Assessment of Brain Metabolism in Perinatally HIV-Infected Youths Using Accelerated 5D Echo Planar J-Resolved Spectroscopic Imaging.Neuronal-Glia Markers by Magnetic Resonance Spectroscopy in HIV Before and After Combination Antiretroviral TherapyHIV-1 gp120Bal down-Regulates Phosphorylated NMDA Receptor Subunit 1 in Cortical Neurons via Activation of Glutamate and Chemokine Receptors.β-Catenin signaling positively regulates glutamate uptake and metabolism in astrocytes.GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy.NMDARs Adapt to Neurotoxic HIV Protein Tat Downstream of a GluN2A-Ubiquitin Ligase Signaling Pathway.Plasma gelsolin protects HIV-1 gp120-induced neuronal injury via voltage-gated K+ channel Kv2.1.Astrocyte Dysfunctions and HIV-1 Neurotoxicity.Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.Selective Vulnerability of Striatal D2 versus D1 Dopamine Receptor-Expressing Medium Spiny Neurons in HIV-1 Tat Transgenic Male Mice.HIV-associated synaptic degeneration.N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.Development of a primary microglia screening assay and its use to characterize inhibition of system xc- by erastin and its analogs.Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.HIV-1 protein Tat produces biphasic changes in NMDA-evoked increases in intracellular Ca2+ concentration via activation of Src kinase and nitric oxide signaling pathways.The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse modelManganese Control of Glutamate Transporters' Gene Expression.HIV Neuroinfection and Alzheimer's Disease: Similarities and Potential Links?
P2860
Q26766448-78EEA38C-F279-4F82-9667-F819B18BB9E5Q26996061-538DF69D-9D4F-4B15-A1A5-12D99003847AQ26996723-B4C5F8BB-1B2A-4675-A681-BEDBC5EEC709Q30275882-9BAA6DAC-02C1-4356-8691-6B56196D5BCFQ30278962-634BA344-3D06-467B-B6CA-CDC3353D4CF2Q30374429-C3ED4630-8704-4262-99F8-894266B5075EQ33620624-A000EEAC-B4BA-4743-BD7C-8D3E5FEC6AE5Q33694166-2BAC9E60-00A1-41DE-AA67-9CC718A7AA53Q33903612-8F1A87B4-6363-486D-9730-4C19F9D06290Q34714277-DD1D1A7A-D4FD-4859-BC7C-84A66BF3580BQ35006443-0089D7C9-7EFB-4663-B5AF-79E80ED11720Q35051773-88984AB5-894D-4E92-A106-CE9D70D7D3D3Q35220415-1A8CEDC7-040A-45DC-92BF-C80D2DCF1093Q36131217-B62D284E-98A0-4E26-B3A0-E26A2705E166Q36463660-18237284-494D-40E4-A9C5-92095FB68DDFQ36558451-776721D6-430C-435E-B004-FCAE34BB3DABQ37246158-AB5A564D-3452-40BB-9EEB-0CBB08BF08F7Q37335823-74CD8262-CA2D-4162-AFC5-5D88D7742B39Q37340889-C2B34D32-CF51-4187-ABF6-05B7314DA388Q37504979-C189EEFE-0CE0-4D7F-AF1C-CFBD93EBF29DQ37524897-45A1DBA2-C920-4C16-A934-27433334D0D7Q38192643-0E9D4D8F-8BCF-44BE-BD5A-7A0E9195FF55Q38437153-B6512848-04B2-4074-9D7E-BA9CB1AD46ABQ38803243-4CCA1B23-77DB-429C-A59E-6F03721C2C80Q40066321-8F14DEE8-B6CD-4C8F-B583-05FAEC03D0D8Q40113255-4F5AC145-7560-4B4A-8874-8681D60EAC7EQ41682361-7BD7215F-53AB-4816-A34D-F13A6E3C4314Q42026016-FFD5F21F-AD64-4897-98ED-E3A1E8CA1532Q42229248-DB855410-1D1A-4604-BB7B-D8C004837F9EQ42235552-3317275A-E670-4990-9B06-E2CDFEA6DF38Q47923208-4F4CE192-890F-4ECC-8FEF-5C708D0706EEQ58750745-4BAE7FCA-E29C-4108-8936-331BFAA50214
P2860
Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeting the glutamatergic sy ...... iated neurocognitive disorders
@en
type
label
Targeting the glutamatergic sy ...... iated neurocognitive disorders
@en
prefLabel
Targeting the glutamatergic sy ...... iated neurocognitive disorders
@en
P2093
P2860
P921
P1476
Targeting the glutamatergic sy ...... iated neurocognitive disorders
@en
P2093
Barbara S Slusher
Camilo Rojas
Mariana Figuera-Losada
Michelle C Potter
P2860
P2888
P304
P356
10.1007/S11481-013-9442-Z
P577
2013-04-04T00:00:00Z
2013-06-01T00:00:00Z